In-Vitro Evaluation of Thrombolytic Activity of Five Medicinal Plants Available In Bangladesh
- Department of Biotechnology and Genetic Engineering, Faculty of Applied Science and Technology, Islamic University, Kushtia-7003, Bangladesh
- Department of Pharmacy, Faculty of Science and Engineering, International Islamic University Chittagong, Chittagong, Bangladesh
- Department of Applied Nutrition and Food Technology, Faculty of Applied Science and Technology, Islamic University, Kushtia-7003, Bangladesh
Abstract
The use of plants and plants derived substances increases day by day for the discovery of therapeutic agents. The current research is directed towards searching naturally occurring thrombolytic agents from plant origin since thrombolytic agents play a crucial role in developing various human diseases such as atherothrombotic diseases, pulmonary embolism, and myocardial infarction etc. The present study was designed to study the thrombolytic properties of five medicinal plants found in Bangladesh namely Ixora nigricans, Amomum dealbatum Roxb, Zingiber montana, Ampelocissus barbata, Borreria laevis. An in vitro thrombolytic model was used to evaluate the clot lysis effect of crude methanol extract of plants along with Streptokinase as a positive and water as a negative control. Using the in vitro thrombolytic mode, Ixora nigricans, Amomum dealbatum Roxb, Zingiber montana, Ampelocissus barbata, Borreria laevis demonstrated (35.07 ± 0.57)%, (19.21 ± 0.01)%, (18.89 ± 0.06)%, (25.32 ± 0.01)%, (19.46 ± 0.02)% clot lysis respectively. Among the plants studied Ixora nigricans and Ampelocissus barbata showed significant % of clot lysis (35.07 ± 0.57) % and (25.32 ± 0.01) % respectively with reference to Streptokinase (75.26 ± 0.48)%. Through our study it was observed that the studied plants possess thrombolytic properties that could lyse the blood clot in vitro; however, in vivo clot dissolving properties and active component(s) of these plants are yet to be explored. Once found they could be incorporated as a thrombolytic agent for the treatment of atherothrombotic diseases.